Psychopharmacologic Treatment of Children and Adolescents with Anxiety Disorders

Child and Adolescent Psychiatric Clinics of North America

Volumn 21, Issue 3, 2012, Pages 527-539

  Strawn, Jeffrey R ^a,b   Sakolsky, Dara J ^c   Rynn, Moira A ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Benzodiazepine; Generalized anxiety disorder; Selective serotonin norepinephrine reuptake inhibitor; Selective serotonin reuptake inhibitor; Separation anxiety disorder; Social phobia

Indexed keywords

ALPRAZOLAM; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LORAZEPAM; PAROXETINE; PLACEBO; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; AGITATION; ANOREXIA; ANXIETY DISORDER; ASTHENIA; BEHAVIOR DISORDER; CHILD; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COGNITIVE THERAPY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; IRRITABILITY; MEDICAL RESEARCH; MOTOR ACTIVITY; NAUSEA; OPPOSITIONAL BEHAVIOR; OVERANXIOUS DISORDER; PAIN; PANIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SEDATION; SEPARATION ANXIETY; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; STOMACH PAIN; SUICIDAL IDEATION; VOMITING; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADOLESCENT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; BENZODIAZEPINES; CHILD; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 84863859415     PISSN: 10564993     EISSN: 15580490     Source Type: Journal    
DOI: 10.1016/j.chc.2012.05.003     Document Type: Review

References (61)

1. Beesdo K., Pine D.S., Lieb R., et al. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry 2010, 67:47-57.
2. Beesdo K., Knappe S., Pine D.S. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin North Am 2009, 32:483-524.
3. Birmaher B., Yelovich A.K., Renaud J. Pharmacologic treatment for children and adolescents with anxiety disorders. Pediatr Clin North Am 1998, 45:1187-1204.
4. Foley D.L., Goldston D.B., Costello E.J., et al. Proximal psychiatric risk factors for suicidality in youth: the Great Smoky Mountains Study. Arch Gen Psychiatry 2006, 63:1017-1024.
5. Jacobson C.M., Muehlenkamp J.J., Miller A.L., et al. Psychiatric impairment among adolescents engaging in different types of deliberate self-harm. J Clin Child Adolesc Psychol 2008, 37:363-375.
6. Costello E.J., Janiszewski S. Who gets treated?. Factors associated with referral in children with psychiatric disorders. Acta Psychiatr Scand 1990, 81:523-529.
7. Chavira D.A., Stein M.B., Bailey K., et al. Child anxiety in primary care: prevalent but untreated. Depress Anxiety 2004, 20:155-164.
8. Walkup J.T., Albano A.M., Piacentini J., et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008, 359:2753-2766.
9. Compton S.N., Walkup J.T., Albano A.M., et al. Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods. Child Adolesc Psychiatry Ment Health 2010, 4:1.
10. Kendall P.C., Compton S.N., Walkup J.T., et al. Clinical characteristics of anxiety disordered youth. J Anxiety Disord 2010, 24:360-365.
11. Verduin T.L., Kendall P.C. Differential occurrence of comorbidity within childhood anxiety disorders. J Clin Child Adolesc Psychol 2003, 32:290-295.
12. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959, 32:50-55.
13. Rynn M.A., Siqueland L., Rikels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001, 158:2008-2014.
14. Maskowsky J., Mogg K., Bradley B.P., et al. A preliminary investigation of the neural correlates of treatment in adolescents with generalized anxiety disorder. J Child Adolesc Psychopharmacol 2010, 20:105-111.
15. Fairbanks J.M., Pine D.S., Tancer N.K., et al. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol 1997, 7:17-29.
16. Birmaher B., Waterman G.S., Ryan N., et al. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994, 33:993-999.
17. Birmaher B., Axelson D.A., Monk K., et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003, 42:415-423.
18. Rynn M.A., Riddle M.A., Yeung P.P., et al. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007, 164:290-300.
19. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry 2002, 41:1061-1069.
20. Birmaher B., Khetarpal S., Brent D., et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 1997, 36:545-553.
21. Kutcher S.P., Reiter S., Gardner D.M., et al. The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatr Clin North Am 1992, 15:41-67.
22. Simeon J.G., Ferguson H.B. Alprazolam effects in children with anxiety disorders. Can J Psychiatry 1987, 32:570-574.
23. Buspirone package insert 2010, Bristol-Meyers Squibb Company, Princeton, NJ.
24. Salazar D.E., Frackiewicz E.J., Dockens R., et al. Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults. J Clin Pharmacol 2001, 41:1351-1358.
25. Ballenger J.C., Burrows G.D., DuPont R.L., et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry 1988, 45:413-422.
26. Rickels K., Case G., Downing R.W. Long-term diazepam therapy and clinical outcome. JAMA 1983, 250:767-771.
27. Tesar G., Rosenbaum J., Pollack M., et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry 1987, 15:16-21.
28. Simeon J.G., Ferguson H.B., Knott V., et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 1992, 31:29-33.
29. Wagner K.D., Berard R., Stein M.B., et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004, 61:1153-1162.
30. March J.S., Entusah A.R., Rynn M., et al. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 2007, 62:1149-1154.
31. Beidel D.C., Turner S.M., Sallee F.R., et al. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry 2007, 46:1622-1632.
32. Compton S.N., Grant P.J., Chrisman A.K., et al. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001, 40:564-571.
33. Chavira D.A., Stein M.B. Combined psychoeducation and treatment with selective serotonin reuptake inhibitors for youth with generalized social anxiety disorder. J Child Adolesc Psychopharmacol 2002, 12:47-54.
34. Klein R.G., Koplewicz H.S., Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 1992, 31:21-28.
35. Bernstein G.A., Garfinkel B.D., Borchardt C.M. Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry 1990, 29:773-781.
36. Berney T., Kolvin I., Bhate S.R., et al. School phobia: a therapeutic trail with clomipramine and short-term outcome. Br J Psychiatry 1981, 138:110-118.
37. Bernstein G.A., Borchardt C.M., Perwien A.R., et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry 2000, 39:276-283.
38. Graae F., Milner J., Rizzotto L., et al. Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994, 33:372-376.
39. Renaud J., Birmaher B., Wassick S.C., et al. Use of selective serotonin reuptake inhibitors for the treatment of childhood panic disorder: a pilot study. J Child Adolesc Psychopharmacol 1999, 9:73-83.
40. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001, 344:1279-1285.
41. Walkup J., Labellarte M., Riddle M.A., et al. Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. J Child Adolesc Psychopharmacol 2002, 12:175-188.
42. Clark D.B., Birmaher B., Axelson D., et al. Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 2005, 44:1263-1270.
43. Ginsburg G.S., Kendall P.C., Sakolsky D., et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol 2011, 79:806-813.
44. Geller D., Donnelly C., Lopez F., et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007, 46:1119-1127.
45. Kendall P.C. Treating anxiety disorders in children: results of a randomized clinical trial. J Consult Clin Psychol 1994, 62:100-110.
46. Kendall P.C., Flannery-Schroeder E., Panichelli-Mindel S.M., et al. Therapy for youths with anxiety disorders: a second randomized clinical trial. J Consult Clin Psychol 1997, 65:366-380.
47. James A., Soler A., Weatherall R. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2005, 19. CD004690.
48. Bridge J.A., Iyengar S., Salary C.B., et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007, 297:1683-1696.
49. Connolly S.D., Bernstein G.A. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2007, 46:267-283. Work Group on Quality Issues.
50. Strawn J.R., Wehry A.M., DelBello M.P., et al. Establishing the neurobiologic basis of treatment for children and adolescents with generalized anxiety disorder. Depress Anxiety 2012, 29:328-339.
51. McClure E.B., Adler A., Monk C.S., et al. fMRI predictors of treatment outcome in pediatric anxiety disorders. Psychopharmacology (Berl) 2007, 191:97-105.
52. Sakolsky D., Nurmi E., Birmaher B., et al. Association of GRIK4 with treatment response in the Child/Adolescent Anxiety Multimodal Study (CAMS). Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) October 26-31, 2010.
53. Sakolsky D., Nurmi E., Birmaher B., et al. Academy of Child and Adolescent Psychiatry in the Child/Adolescent Anxiety Multimodal Study (CAMS). American Academy of Child and Adolescent Psychiatry (AACAP) and Canadian Academy of Child and Adolescent Psychiatry (CACAP) Joint Annual Meeting October 18-23, 2011.
54. Pollack M.H., Jensen J.E., Simon N.M., et al. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Progr Neuropsychopharmacol Biol Psychiatry 2008, 32:739-743.
55. Yücel M., Harrison B.J., Wood S.J., et al. Functional and biochemical alterations of the medial frontal cortex in obsessive-compulsive disorder. Arch Gen Psychiatry 2007, 64:946-955.
56. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005, 10:808-819.
57. Palucha A., Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007, 115:116-147.
58. Rynn M., Puliafico A., Heleniak C., et al. Advances in pharmacotherapy for pediatric anxiety disorders. Depress Anxiety 2011, 28:76-87.
59. Sallee F.R., Sethuraman G., Sine L., et al. Yohimbine challenge in children with anxiety disorders. Am J Psychiatry 2000, 157:1236-1242.
60. Hoehn-Saric R., Merchant A.F., Keyser M.L., et al. Effects of clonidine on anxiety disorders. Arch Gen Psychiatry 1981, 38:1278-1282.
61. Sallee F.R., Richman H., Sethuraman G., et al. Clonidine challenge in childhood anxiety disorder. J Am Acad Child Adolesc Psychiatry 1998, 37:655-662.